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ABSTRACT

A newly-developed platform, the Illumina TruSeq Methyl Capture EPIC library prep (TruSeq EPIC),
builds on the content of the Infinium MethylationEPIC Beadchip Microarray (EPIC-array) and
leverages the power of next-generation sequencing for targeted bisulphite sequencing. We
empirically examined the performance of TruSeq EPIC and EPIC-array in assessing genome-wide
DNA methylation in breast tissue samples. TruSeq EPIC provided data with a much higher density
in the regions when compared to EPIC-array (~2.74 million CpGs with at least 10X coverage vs
~752 K CpGs, respectively). Approximately 398 K CpGs were common and measured across the
two platforms in every sample. Overall, there was high concordance in methylation levels
between the two platforms (Pearson correlation r = 0.98, P < 0.0001). However, we observed
that TruSeq EPIC measurements provided a wider dynamic range and likely a higher quantitative
sensitivity for CpGs that were either hypo- or hyper-methylated (β close to 0 or 1, respectively). In
addition, when comparing different breast tissue types TruSeq EPIC identified more differentially
methylated CpGs than EPIC-array, not only out of additional sites interrogated by TruSeq EPIC
alone, but also out of common sites interrogated by both platforms. Our results suggest that both
platforms show high reproducibility and reliability in genome-wide DNA methylation profiling,
while TruSeq EPIC had a significant improvement over EPIC-array regarding genomic resolution
and coverage. The wider dynamic range and likely higher precision of the estimates by the TruSeq
EPIC may lead to the identification of novel differentially methylated markers that are associated
with disease risk.

Introduction
DNA methylation is an essential epigenetic
mechanism involved in gene regulation in the
human genome. It is a DNA modification whereby
a methyl group is added to Cytosine-5 at
C-phosphate-G (CpG) dinucleotides. Methylation
of CpG islands at the 5ʹ end of the promoter
region of a gene is generally associated with gene
repression [1]. DNA methylation reflects both
environmental and genetic influences and varies
across individuals [2,3,4]. Aberrant DNA methyla
tion can lead to dysregulation of cellular processes
and plays a critical role in the pathophysiology of
various diseases including diabetes, cardiovascular
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diseases, and cancer [5,6,7,8]. Investigation of var
iation in DNA methylation in recent epigenomewide association studies (EWAS) in large numbers
of human samples have provided remarkable
insight into the biological mechanisms that under
lie health outcomes [9,10,11].
The success of methylation studies requires the
development of methods that can measure DNA
methylation simultaneously across the genome.
Whole-genome bisulphite sequencing (WGBS) is
considered the gold standard method to interrogate
DNA methylation with the highest genomic cover
age and nucleotide resolution for quantification of
DNA methylation [12]. However, the high cost and
high data analysis burden of this method make it
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infeasible for studies with a large number of samples.
The Illumina Infinium Methylation EPIC Beadchip
Microarray (EPIC-array) provides a cost-effective
platform that has been commonly used for highthroughput profiling of DNA methylation for over
850 K CpGs [13,14]. This microarray-based method
uses a fixed number of probes to survey specific
genomic loci across the genome; thus, it is unable
to expand beyond genomic regions dictated by both
the number and specificity of the probes, thereby
limiting the comprehensive screening of the genome
for altered methylation loci. EPIC-array also suffers
from the limitations inherent to the hybridization
technology such as errors introduced by probe crosshybridization when measuring methylation level. To
overcome these limitations of EPIC-array and
reduce sequencing-associated costs and processing
time, Illumina, Inc. has recently developed a new
platform, the TruSeq Methyl Capture EPIC Library
kit (TruSeq EPIC), which builds on EPIC-array con
tent with additional emerging epigenetic regions of
interest [15]. It leverages the power of nextgeneration sequencing (NGS) to perform targeted
bisulphite sequencing and covers approximately
3.34 million CpG sites. TruSeq EPIC provides
a balanced, intermediate option between WGBS
and EPIC-array to survey the human methylome
with an increased coverage and resolution.
As TruSeq EPIC complements and expands on
EPIC-array, and the latter has been commonly
used in recent EWAS of large human samples,
TruSeq EPIC may become an attractive option
for future EWAS that aims to enhance genome
coverage and resolution but maintain research
continuity. Only one study has been recently
reported to compare the performance of TruSeq
EPIC and EPIC-array in cord blood [16].
However, no evaluation has been done to compare
the two platforms in human breast tissue.
Furthermore, no study has yet examined the per
formance of TruSeq EPIC in investigating interindividual variation from human tissue samples,
which is the main interest in EWAS. It is also
unclear whether the higher resolution provided
by TruSeq EPIC may help detect more genomic
sites showing inter-individual variation. To
address these issues, we compared the two plat
forms on DNA methylation profiling in 11 human
breast tissue samples, including 3 normal breast

tissue samples from healthy women, 4 breast
tumour and 4 matched adjacent normal breast
tissue samples from breast cancer patients. We
first evaluated the technical performance of
TruSeq EPIC in these tissue samples and then
compared the two methods across key functional
genomic regions in the context of their coverage
and concordance of methylation calls. Lastly, as
proof-of-principle, in this small sample, we exam
ined the utility of the two methods in studying
inter-individual variation and compared their per
formance in detecting genomic sites that are dif
ferentially methylated across breast tissue types.
The goal of this study is to provide an empirical
comparison of the two methods to inform
researchers on considering and choosing an
appropriate platform for future EWAS.

Results
Overview of TruSeq EPIC and EPIC-array analyses
of human breast tissue samples

Sample information on the 11 breast tissue samples is
presented in Table 1. We first evaluated the technical
performance of the TruSeq EPIC method in these
samples. Mapping efficiency, sequencing duplication
rates, and sequencing bait specificities are summar
ized in Table 2. On average, approximately 56 million
paired-end reads were generated per sample, of which
48 million aligned uniquely to the bisulphiteconverted human reference genome (hg19/
GRCH37). Thirty-two million reads remained after
removal of duplicate reads and 96% of the reads were
found within the target region. TruSeq EPIC is
Table 1. Sample information for the 11 beast tissue samples in
this study.
Sample ID
K1
K2
K3
AN1
AN2
AN3
AN4
T1
T2
T3
T4

Tissue Type
Normal
Normal
Normal
Adjacent Normal
Adjacent Normal
Adjacent Normal
Adjacent Normal
Tumour
Tumour
Tumour
Tumour

Age
70
56
63
71
56
63
43
71
56
63
43

Race
White
White
White
White
White
White
White
White
White
White
White

Subtype info

ER+/PR+/HER2ER+/PR-/HER2ER+/PR+/HER2ER-/PR-/HER2 +

Note: T and AN samples were paired samples from same breast cancer
patients, K samples from healthy women were matched with T and
AN samples on age (within one year) and race.
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Table 2. Summary of sequencing alignment and duplication rates for the 11 breast tissue samples in the study for TruSeq EPIC.
Sample
ID
K1
K2
K3
AN1
AN2
AN3
AN4
T1
T2
T3
T4
Average

Raw Paired
Reads
48,362,869
57,267,567
43,425,858
54,299,349
59,511,340
52,000,198
62,153,856
84,397,277
57,345,325
67,981,266
61,435,469
58,925,489

Paired Reads
Analyzed
45,836,705
54,819,987
41,897,565
51,273,091
56,987,839
49,803,822
59,671,655
80,140,512
54,985,466
65,416,988
59,012,172
56,349,618

Unique
Aligned
38,908,769
46,870,975
35,948,675
43,424,920
48,549,950
42,539,248
51,034,628
68,142,382
46,779,470
55,886,719
50,443,336
48,048,097

Mapping Efficiency
(%)
84.9
85.5
85.8
84.7
85.2
85.4
85.5
85.1
85.1
85.5
85.5
85.3

designed to have >90% overlap with the EPIC-array
target regions and capture approximately up to
3.34 million CpG sites in its bait-targeted region. In
our breast tissue samples, we detected on average
3.32 million CpG sites at any read depth. The number
of CpGs detected at different read depths are shown in
Figure 1 and Table 3. We detected approximately
2.74 million CpGs with at least 10X coverage in all
of our samples. Our samples have an average read
depth of 40X.
The EPIC-array is designed to capture 862,927
CpG sites in human genome, of which 587,611
CpG sites are common to the TruSeq EPIC plat
form by design. After comprehensive quality con
trol [17], we detected an average of 752,483 CpGs
across our 11 breast tissue samples using EPICarray, of which 507,206 and 398,579 CpGs were
also captured by TruSeq EPIC with at least 1X and
10X coverage, respectively.
Comparison of genome coverage by TruSeq EPIC
and EPIC-array

We evaluated the number and the distributions of
CpGs that were designed to be captured and were

Duplication Rate
(%)
53.1
29.6
33.5
41.2
32.1
26.5
28.8
43.5
32.5
27.5
29.7
34.4

Usable
Aligned
18,247,939
32,989,161
23,903,913
25,535,830
32,978,423
31,254,585
36,331,972
38,532,574
31,583,044
40,510,431
35,447,364
31,574,112

Reads in Target Region
(%)
95.73
94.78
96.48
94.43
95.76
95.78
96.01
94.96
95.88
96.23
96.06
95.63

Figure 1. Genomic coverage of the TruSeq EPIC at different
sequencing depths for the 11 breast tissue samples. T, breast
tumour tissue; AN, adjacent normal breast tissue; K, normal
breast tissue.

empirically captured by TruSeq EPIC and EPICarray with respect to CpG-island context and other
genomic functional features. Out of approximately
3.34 million CpGs designed to be captured by
TruSeq EPIC, 50%, 7%, 6%, and 37% belong to
CpG islands, shores, shelves and open sea regions,
respectively (Figure 2a); 13%, 17%, 6%, 19%, 2%,

Table 3. The number of CpGs detected by Truseq EPIC at different sequencing depths.
Sample ID
K1
K2
K3
AN1
AN2
AN3
AN4
T1
T2
T3
T4
Average

≥1X
3,326,519
3,324,716
3,325,728
3,324,094
3,323,823
3,318,153
3,316,749
3,322,051
3,322,979
3,319,143
3,320,280
3,322,203

≥10X
2,906,961
2,831,944
2,826,205
2,862,913
2,810,763
2,564,387
2,544,485
2,725,132
2,815,293
2,592,923
2,702,866
2,743,988

≥20X
1,935,191
1,791,353
1,763,117
1,873,173
1,763,491
1,404,857
1,355,798
1,642,768
1,805,303
1,468,107
1,664,471
1,678,875

≥30X
1,147,526
997,678
981,020
1,087,939
990,840
695,249
635,128
902,016
1,042,472
771,884
940,301
926,550

≥40X
649,988
521,914
520,099
602,832
529,811
318,028
265,809
475,439
575,265
392,301
509,364
487,350

≥50X
345,863
249,524
255,283
313,637
262,480
129,452
96,014
238,078
300,211
193,353
263,823
240,702
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8%, 10% and 26%, belong to promoter, 5’UTR,
exon, intron, 3ʹUTR, TSS200, TSS1500, and inter
genic regions, respectively (Figure 2b); and 47%,
40%, 39%, and 6% belong to DNaseI hypersensi
tive, open chromatin, TFBS, and FANTOM5
enhancer regions, respectively (Figure 2c). In our
breast tissue samples, we detected the majority of
the CpGs (>80%) at these genomic features with at
least 10X coverage (Figure 2a-c). The observed
distribution of CpGs with genomic features was
also similar to the expected by design (Figure
2a-c).
Compared to EPIC-array, TruSeq EPIC
detected more CpGs in absolute numbers at
each functional annotation class with no surprise
(between 1.5 and 25.8 times more), as this meth
odology is not limited by probes and can there
fore interrogate CpG sites comprehensively
(Figure 2a-c). The proportion of CpG loci
assessed by TruSeq EPIC and EPIC-array did
not differ substantially with respect to genomic
functional features except for CpG-islands,
where 51% of CpGs detected by TruSeq EPIC
were located in CpG-islands, compared to only
19% detected by EPIC-array (Figure 2a). Our
data also showed that TruSeq EPIC, compared
to EPIC-array, had slightly increased proportions
of CpGs in promoter (13% vs. 7%), 5ʹ-UTR (18%
vs. 13%), and exon (6% vs. 5%) regions, but
significantly increased proportions of CpGs in
open chromatin (40% vs. 6%) and TFBS (39%
vs. 8%) regions (Figure 2b-c). Even though the
two platforms are designed to cover the same
CpG-island and promotor regions, TruSeq EPIC
covered these regions at a much higher density
and resolution, i.e. TruSeq EPIC detected more
CpGs at the same promotor region when com
pared to EPIC-array. Likewise, TruSeq EPIC
generally assayed other genomic regions at
a much higher density.
We also evaluated the distribution of CpGs
detected by TruSeq EPIC and EPIC-array on
each chromosome (Figure 2d). In our breast
tissue samples, EPIC-array detected less than
3.5% of CpGs on each chromosome in the
human methylome, while TruSeq EPIC signifi
cantly increased the proportion by 4–6 folds,
ranging between 7% and 19% of CpGs on

different chromosomes. Because all samples
were from women, no CpG sites were detected
on chromosome Y as expected. Compared to the
autosomal chromosomes, the X-chromosome has
a relatively lower coverage by TruSeq EPIC (7%)
and an almost negligible coverage by EPIC-array
after quality control.
Comparison of methylation signal calling by
TruSeq EPIC and EPIC-array

The distribution of methylation β values from
both TruSeq EPIC and EPIC-array platforms
followed a bimodal distribution as expected.
The dynamic range, the range between the lar
gest and the smallest values of the measure
ments, for methylation β values derived from
EPIC-array was more condensed compared to
those derived from TruSeq EPIC (Figure 3).
Among the 398,579 common CpGs that were
detected by both platforms in all samples, the
sample-based correlation between methylation β
values from the two platforms was high and
increased slightly with increasing coverage (aver
age r = 0.962, 0.966, and 0.968 at 10X, 30X and
50X, respectively). In addition, high correlations
were generally observed for all three breast tissue
types, with the highest correlation in normal
breast tissue, followed by adjacent normal breast
tissue, and the lowest in tumour breast tissue
(Figure 4).
Although the overall correlation between
TruSeq EPIC and EPIC-array methylation β
values was high (Pearson correlation of 0.98,
p < 2.2 X10−16), we observed that the most
discrepant signals between the two methodolo
gies occured at CpGs with extremes of either low
(close to 0) or high (close to 1) methylation β
values (Figure 5a-d). For CpGs with low β
values, the corresponding region showed that
TruSeq EPIC measurements clustered close to 0
and corresponding β values from EPIC-array
tended to be larger; for CpGs with high β values,
the corresponding region showed that TruSeq
EPIC measurements clustered close to 1 and
corresponding β values from EPIC-array tended
to be smaller. The dynamic range of methylation
β values from EPIC-array was narrower and
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a

b

c

d

Figure 2. The distribution of CpGs by different genomic annotations from TruSeq EPIC (≥10X) and EPIC-array platforms. (a) CpGisland context; (b) genomic function context; (c) regulatory region context; (d) chromosome.

more condensed compared to that of TruSeq
EPIC. This pattern was consistently observed
regardless of breast tissue type (Figure 5a-c).

To assess the number of CpGs with concordant
and discordant methylation levels between the two
methodologies, we grouped the CpGs into three
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a

b

c

d

Figure 3. Distribution of methylation β values from the two platforms for our 11 breast tissue samples. (a) the common CpGs across
the two platforms in TruSeq EPIC (≥10X); (b) the common CpGs in EPIC-array; (c) all CpGs detected in TruSeq EPIC (≥10X); (d) all CpG
detected in EPIC-array.

Figure 4. Pearson correlation between methylation β-values of
the common CpGs across TruSeq EPIC (≥10X) and EPIC-array
platforms by different sequencing depth for our 11 breast tissue
samples.

categories based on β values: hypomethylated
(β < 0.3), hemimethylated (0.3 ≤ β ≤ 0.7), and

hypermethylated (β > 0.7). We observed that 86% of
the CpGs were concordant between the two platforms
with 32% hypo- and 35% hyper-methylated (Table 4).
Approximately 5% of the CpGs were detected as
hypomethylated by TruSeq EPIC but were detected
as hemimethylated by EPIC-array, compared to 0.5%
CpGs that were detected as hypomethylated by EPICarray but were detected as hemimethylated by TruSeq
EPIC. On the other hand, 6% of the CpGs were
detected as hypermethylated by TruSeq EPIC but
were detected as hemimethylated by EPIC-Array,
compared to 2% of the CpGs that were detected as
hypermethylated by EPIC-array but were detected as
hemimethylated by TruSeq EPIC. We did not observe
any common feature among these discrepant CpG
sites between the two methods, such as sharing similar
genomic or functional regions (Supplementary Table
1). It appeared that TruSeq EPIC tended to have
measures closer to 0 or 1 at extremes compared to
EPIC-array. This clustered distribution of CpGs at the
lower and upper extremities of methylation suggested

EPIGENETICS
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Figure 5. Scatterplots and Pearson correlations of the mean methylation β values for the common CpGs from TruSeq EPIC (≥10X)
and EPIC-array data. Red dotted lines denote Y = X. (a) T samples; (b) AN samples; (c) K samples; (d) all samples combined.

Table 4. Concordance of the mean methylation β values of the common CpGs from TruSeq EPIC (≥10X)
and EPIC-array platforms.
EPIC-array
Hypo (β < 0.3)
Hemi (0.3 ≤ β ≤ 0.7)
Hyper (β > 0.7)

Hypo (β < 0.3)
116,474
20,982
19

that the TruSeq EPIC may have a wider dynamic
range and likely a higher quantitative sensitivity of
the measurements than EPIC-array.
Comparison of the identification of differentially
methylated positions (DMPs) by TruSeq EPIC and
EPIC-array

For the 398,579 common CpGs that were detected in
all samples across both platforms, we further exam
ined the correlation of the change in methylation β

TruSeq EPIC
Hemi (0.3 ≤ β ≤ 0.7)
1,465
77,966
8,632

Hyper (β > 0.7)
10
25,337
147,693

values (∆β) from the two methods in any pairwise
comparison of two tissue types (Figure 6). We found
that the correlation of ∆β values was high in tumour
vs. normal and tumour vs. adjacent normal breast
tissue comparisons (r = 0.88 and 0.90, respectively;
all p < 2.2x10−16), while the correlation was moderate
in when comparing adjacent normal to normal breast
tissue (r = 0.54, p < 2.2x10−16). Similar to the beha
viour we observed with the correlation of β values
between the two methodologies, we also observed that
discrepant signals happened at CpGs with extremes of
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a

b

c

Figure 6. Scatterplots and Pearson correlations of the mean differences of methylation β values (∆β) for the common CpGs between two
tissue types from TruSeq EPIC (≥10X) and EPIC-array data. Red dotted lines denote Y = X. (a) T vs. K; (b) T vs. AN; and (c) AN vs. K.

∆β values (Figure 6a-c). As the absolute difference in
β values (|∆β|) between any two tissue types increased,
the corresponding regions in the two extremes
showed more CpGs with larger |∆β| values measured
from TruSeq EPIC than those from EPIC-array. This
pattern was consistently observed in all pairwise com
parisons between tissue types (Figure 6a-c), but was
most pronounced in the comparison between adja
cent normal vs. normal breast tissue (Figure 6c).
Using |∆β| ≥0.2 as the cut-off, we assessed the
number of CpGs with concordant and discordant
differences in methylation levels between the two
methodologies (Table 5). In the comparison
between tumour vs. normal breast tissue, 90% of
the CpGs had concordant ∆β values between the
two platforms, with 6% having |∆β| consistently
greater than 0.2. Compared to 8.7% of the CpGs
that had |∆β| values greater than 0.2 from TruSeq
EPIC but less than 0.2 from EPIC-array, only 1.0%
of the CpGs had |∆β| values greater than 0.2 from

Table 5. Concordance of the mean differences of methylation β
values (∆β) between two tissue types from TruSeq EPIC (≥10X)
and EPIC-array data.
T vs. K
TruSeq EPIC
EPIC-array Δβ Category Δβ < −0.2 −0.2 ≤ Δβ
Δβ > 0.2
≤0.2
Δβ < −0.2
16,425
1,319
0
−0.2 ≤ Δβ
19,263
333,883
15,628
≤0.2
Δβ > 0.2
0
2,679
9,382
T vs. AN
TruSeq EPIC
EPIC-array
Δβ Category Δβ < −0.2 −0.2 ≤ Δβ Δβ > 0.2
≤0.2
Δβ < −0.2
20,458
1,524
0
−0.2 ≤ Δβ
22,002
335,620
11,297
≤0.2
Δβ > 0.2
0
2,026
5,652
AN vs. K
TruSeq EPIC
EPIC-array
Δβ Category Δβ < −0.2 −0.2 ≤ Δβ Δβ > 0.2
≤0.2
Δβ < −0.2
28
22
0
−0.2 ≤ Δβ
2,539
392,731
3,242
≤0.2
Δβ > 0.2
0
8
9

EPIC-array but less than 0.2 from TruSeq EPIC.
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There were no CpGs with extreme differences in
∆β values (i.e. |∆β| greater than 0.2 but ∆β in
opposite direction from TruSeq EPIC and EPICarray, Table 5 upper section). Similar patterns and
numbers were observed in the comparison
between tumour vs. adjacent normal breast tissue
(Table 5 middle section). The most striking dis
crepancies were observed in the comparison
between adjacent normal vs. normal breast tissue.
Approximately 98% of CpGs had concordant ∆β
values between the two platforms, but only 37
CpGs (less than 0.01%) had |∆β| consistently
greater than 0.2. While the |∆β| values of 5,781
CpGs (1.5%) were greater than 0.2 from TruSeq
EPIC, their corresponding |∆β| values from EPICarray were less than 0.2. On the other hand, only
30 CpGs (less than 0.008%) had |∆β| values greater
than 0.2 from EPIC-array but less than 0.2 from
TruSeq EPIC (Table 5 lower section). This finding
indicates that TruSeq EPIC might be more sensi
tive to detect subtle difference in DNA methyla
tion between adjacent normal and normal breast
tissue.
We further assessed the number of DMPs
detected by TruSeq EPIC and EPIC-array (Figure
7) in pairwise tissue comparisons. In the compar
ison between tumour vs. normal breast tissue,
123,118 and 72,171 out of the common 398,579

9

CpGs were identified as DMPs by TruSeq EPIC
and EPIC-array, respectively, with 56,758 overlap
ping DMPs across the two methods. While 54% of
the DMPs detected by TruSeq EPIC were missed
by EPIC-array, only 21% of the DMPs detected by
EPIC-array were missed by TruSeq EPIC (Figure
7a left panel). Similarly, TruSeq EPIC detected
approximately twice as many DMPs than EPICarray in the comparison between tumour vs. adja
cent normal breast tissue. The number and pro
portion of detected and missed DMPs by the two
platforms were also similar (Figure 7a middle
panel). Most interestingly, we observed the largest
discrepancy between the two platforms in the
comparison between adjacent normal vs. normal
breast tissue. As expected, with the smaller differ
ence between adjacent normal and normal breast
tissue, we detected 17,007 and 1,345 DMPs using
TruSeq EPIC and EPIC-array, respectively, with
447 overlapping DMPs across the two methods.
TruSeq EPIC detected 13 times more DMPs than
EPIC-array and >97% of the DMPs detected by the
TruSeq EPIC were missed by the EPIC-array
(Figure 7a right panel). This finding indicates
that TruSeq EPIC might be more robust and sen
sitive to detect subtle differences between similar
tissue types. As , our data demonstrated that
TruSeq EPIC may detect more variable CpG sites

a

b

Figure 7. The number of differentially methylated positions (DMPs) between tissue types identified by TruSeq EPIC (≥10X) and EPICarray platforms. DMPs were defined by FDR < 0.05 and |∆β| ≥ 0.1. (a) the common CpGs across the two platforms; (b) all CpGs
detected by each platform.
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than EPIC-array out of the common CpGs across
the two platforms.
When considering all CpGs detected by each
platform, TruSeq EPIC provided a more dense
coverage of the epigenome than EPIC-array in
our samples (2.74 million CpGs with at least 10X
coverage vs. 752 K CpGs, respectively). We per
formed EWAS and detected approximately 565 K,
511 K, and 116 K DMPs by TruSeq EPIC in the
comparisons between tumour vs. normal, tumour
vs. adjacent normal, and adjacent normal vs. nor
mal breast tissue, respectively, while the number of
DMPs detected by EPIC-array for the correspond
ing comparisons were, as expected, significantly
reduced to 127 K, 109 K, and 2.4 K, respectively
(Figure 7b). TruSeq EPIC clearly provided a much
higher resolution and allowed for the identifica
tion of more altered methylation sites as well as
the interrogation of methylation heterogeneity in
a given region.
Discussion
High-throughput approaches that measure gen
ome-wide DNA methylation in human samples
have been evolving and refined in the past decade,
including microarray hybridization and sequen
cing technologies. In this study, we empirically
examined and compared two platforms of highthroughput methylome profiling, TruSeq EPIC
and EPIC-array, in human breast tissue samples.
Compared to EPIC-array, TruSeq EPIC surveyed
a much higher density of CpGs in key functional
genomic regions and provided improved coverage
of the human epigenome. For the common CpGs
across the two platforms, these two technologies
were comparable in terms of high correlation and
a high concordance of DNA methylation quantifi
cation. However, TruSeq EPIC showed a wider
dynamic range and a likely higher quantitative
sensitivity at the extremes of methylation levels
(β values close to 0 or 1) compared to EPICarray. Finally, as proof-of-principle, we demon
strated in a small samples that methylation β
values from TruSeq EPIC could distinguish differ
ent breast tissue types and identify more differen
tially-methylated sites.
Although TruSeq EPIC and EPIC-array are
designed to cover similar genomic regions,

TruSeq EPIC has a much higher density of CpGs
and hence a higher coverage of variable sites.
Although EPIC-array represents a significant
improvement in genomic coverage compared to
the earlier array-based platforms (such as
HM450), the majority of regions are still targeted
by just one or a few probes and the methylation
level of one or a few CpG probes may not always
reflect or capture the methylation of the neigh
bouring CpGs. Thus, the ability of EPIC-array to
survey methylation is limited by the fixed number
and the fixed location of CpG probes in a given
genomic region. While TruSeq EPIC is based on
NGS technology that theoretically provides a more
comprehensive assessment of methylation in tar
geted genomic regions, it is of note that the detec
tion of CpG sites also depends on the sequencing
depth and usually a minimum of 10X is required
for reliable measurements [18]. At this sequencing
depth, TruSeq EPIC measured genome-wide DNA
methylation in our breast tissue samples at a much
higher proportion and density in CpG-island, pro
moter, 5 -UTR, open chromatin, and TFBS
regions, which allowed us a more detailed investi
gation of methylation heterogeneity of these reg
ulatory regions [1,19].
The excellent agreement of β values from
TruSeq EPIC and EPIC-array suggested that the
two methodologies were generally comparable and
consistent in quantifying DNA methylation levels.
The high cross-platform reproducibility facilitates
comparative or joint analysis across studies and
ensures research continuity. However, discrepan
cies of methylation calls were also observed, espe
cially at sites with extreme methylation levels (β
values closed to 0 or 1). TruSeq EPIC appeared to
have a wider dynamic range of measured methyla
tion β values compared to a more condensed range
from the EPIC-array. This observation agrees with
previous studies that compared microarray- and
sequencing-derived methylome datasets [16,18,20].
The discrepancies between TruSeq EPIC and
EPIC-array may be attributable to technical differ
ences in DNA methylation assessments, that is,
microarray vs. NGS. EPIC-array is a probe-based
approach that is limited by the specificity, location,
and hybridization processes of the probes. Array
signals could be affected by probe cross-reactivity
or underlying genetic sequence variations that can
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influence the accuracy of probe hybridization
[21,22,23,24]. Genetic variations, such as single
nucleotide polymorphisms (SNPs), can impact
DNA methylation estimates by altering the primary
sequence of nucleotides to add or eliminate a CpG
site or by influencing DNA methylation at nearby
CpG loci [25,26]. Reliable estimates from microar
rays may also be influenced by the probe signal
intensity saturation level at extreme values [27,28].
On the other hand, the sequencing-based TruSeq
EPIC approach is not limited by the probes and can
directly measure SNPs. Thus, this NGS-based plat
form likely provides more accurate estimates of the
actual methylation degrees compared to the arraybased platforms [14,16,29]. In our study, we
observed that the most pronounced differences
between the two methodologies occurred at CpG
sites with extreme methylation levels. The more
condensed dynamic range of the estimates from
EPIC-array may be explained by imperfect hybridi
zation and possible probe signal intensity saturation
at these extreme values. More interestingly, we
observed that the individual-level correlation of esti
mates from the two methods was the highest among
normal breast tissue samples, followed by adjacent
normal breast tissue, and the lowest among breast
tumour tissue samples (Figure 4). These results are
consistent with the notion that tumours are charac
terized by excessive mutations and genomic instabil
ity [30,31]. Somatic mutations in tumours could
interfere with probe hybridization and thus decrease
the accuracy of DNA methylation measurements in
array-based approaches such as EPIC-array, result
ing in a lower correlation between array- and
sequencing-based platforms in this tissue type.
Few studies have examined the performance of
TruSeq EPIC and EPIC-array in measuring genomewide DNA methylation. Only one study has been
recently published by Heiss et al. that compared the
performance of the two methods in cord blood [16].
There are both similarities and major differences
between our study and theirs. First, there are differ
ences in reproducibility and precision. Neither study
included a gold standard such as WGBS, which is
important to assess the accuracy of the measure
ments and understand the discrepancies across the
two methods. Their study assessed reproducibility
with replicates and found EPIC-array had a higher
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correlation coefficient between replicates than
TruSeq EPIC, while our study did not include repli
cates of study samples and thus was unable to assess
the reproducibility of the two methods. However,
reproducibility only reflects the stability, not the
precision of the assays. Furthermore, the lower cor
relation coefficient in TruSeq EPIC in their study did
not take into account the analytic pipeline used for
the sequencing data, such as pooling and imputation,
which could significantly decrease the correlation
coefficient of replicates. Next, there are differences
in tissue samples. Our study compared the two
methods in three different types of breast tissue
(tumour, adjacent normal, and normal), while their
study compared the two methods in cord blood. It is
possible that different tissue types could affect the
performance of the two methods differentially.
Compared to cord blood, breast tissue samples col
lected at much later point in life likely accumulate
more somatic mutations that could interfere with the
hybridization-based EPIC-array more than with
TruSeq EPIC. Thus, it is possible that TruSeq EPIC
may be the better option for measuring DNA methy
lation in tissue samples such as breast, other solid
tissue, or tumours. Lastly, there are differences in
analytic approaches. In our study we directly com
pared different breast tissue types using regression to
identify differentially methylated DNA methylation
sites. We found that TruSeq EPIC was able to iden
tify more differentially methylated CpG sites with
modest differences between tissue types when com
pared to EPIC-array. Meanwhile, the study by Heiss
et al. performed EWAS using a large pre-existing
EPIC-array dataset to form a ‘ground truth’ and
compared the two methods’ ability to discriminate
between positive and negative markers identified by
this EWAS using c-statistics. These two studies had
different analytic approaches and goals that may not
be directly comparable. Furthermore, as their results
showed, there were only slightly differences in c-sta
tistics between the two methods. The differences
may likely be due to correlated errors between the
‘ground truth’ and EPIC-array measurements, as
they used the same technology, leading to a ‘bias in
this benchmark in favor of EPIC,’ as acknowledged
by the authors in their discussion. Nonetheless, both
studies observed a similar genomic coverage regard
ing different functional annotations across the two
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methods as well as the common phenomena that
EPIC-array had a reduced dynamic range of methy
lation measurements compared to TruSeq EPIC.
As proof-of-principle, we performed EWAS
between different breast tissue types in a small sam
ples to examine and compare the utility of TruSeq
EPIC and EPIC-array in identifying differential
methylation. It came no surprise that, compared to
EPIC-array, TruSeq EPIC provided an increased
density and coverage of the epigenome, and as
a result, the detection of more genomic sites showing
differential methylation. Certainly, many of these
sites were only surveyed by TruSeq EPIC through
sequencing. However, even among the common sites
across the two platforms, it is worth noting that
a much larger number and proportion of CpGs
were found to be differentially methylated only by
TruSeq EPIC but not by EPIC-array, comparing to
a much smaller number and proportion of CpGs that
were found differentially methylated only by EPICarray but not by TruSeq EPIC. This is likely due to
the wider dynamic range and/or more accurate mea
surement of methylation β values detected by TruSeq
EPIC as discussed above. These results are consistent
with previous studies comparing array-based and
sequencing-based technologies in genome-wide
DNA methylation profiling [32,33]. Because of the
small sample size in our study, our differential
methylation analysis across tissue types only serves
as a proof-of-principle, which limits our power to
interpret the biological relevance of our results when
compared to EWAS with large number of samples.
Although TruSeq EPIC identified a similarly
larger number of differentially methylated sites
than that from EPIC-array in both comparisons
of tumour vs. normal and tumour vs. adjacent
normal breast tissue, the most intriguing findings
came from the comparison between adjacent nor
mal and normal breast tissue, where 97% of the
differentially methylated sites identified by TruSeq
EPIC were missed by EPIC-array. While the EPICarray suggested negligible differences in methyla
tion profiles between adjacent normal and normal
breast tissue, TruSeq EPIC suggested somewhat
otherwise. Commonly, adjacent normal tissue,
due to its ready availability, was used as
a baseline in comparison with tumour tissue to
identify cancer-associated molecular changes.
Although histologically normal, non-tumourous

tissue adjacent to the tumour is sub-optimal as
a baseline control as it is more likely to contain
molecular changes in global gene expression and
changes in epigenetic markers influenced by the
nearby tumour [34,35]. Thus, findings from such
comparisons should be interpreted with caution
and must consider aberrant changes in adjacent
normal tissue. Our results further suggest that the
ability to detect subtle changes in adjacent normal
tissue may be related to the technology used for
epigenetic profiling and that the inherent limita
tions of EPIC-array in detecting moderate changes
may need to be considered additionally when
interpreting findings from previous studies that
used this technology to compare tumour to adja
cent normal tissue.
To the best of our knowledge, our study is the first
to systematically investigate genome-wide DNA
methylation differences in breast tumour, adjacent
normal, and normal tissue using both TruSeqEPIC
and EPIC-array technologies. We are not aware of
any other studies that make similar comparisons as
ours in breast or other tissue types. However, evi
dence from previous research has suggested that
adjacent normal tissue, though pathologically nor
mal, may not be real ‘normal’ at the molecular level.
One such study examined gene expression in
tumour, adjacent normal, and normal tissue of pros
tate samples using microarray technology and found
distinct gene expression profile for each tissue type,
with a subset of genes similarly deregulated in adja
cent normal and tumour tissue [36]. Similarly, other
studies of breast tissue using microarrays suggested
that adjacent normal tissue is not real ‘normal’ as its
molecular profile can be altered in response to the
adjacent tumour and is, to some extent, similar to
that of tumour tissue [34,35,37]. In our study, we not
only found that there were methylation differences
between normal and adjacent normal tissue, which
was in line with these previous studies, but also
showed that more methylation differences can be
identified using TruSeqEPIC than using EPICarray, which is a novel finding and has not been
assessed in previous studies.
In summary, we performed the first study to
empirically evaluate and compare the performance
of TruSeq EPIC and EPIC-array in interrogating
tissue-specific DNA methylation in breast tissue
samples. Although the two platforms showed an
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excellent overall agreement on measured methyla
tion β values and in the ability to detect sites of
differential methylation between samples, TruSeq
EPIC provided a much denser coverage of the
epigenome as well as a wider dynamic range of
methylation measurements. Based on our results,
TruSeq EPIC identified a larger number of novel
trait-associated sites of differential methylation
between samples that were missed by EPIC-array,
not only out of the sites interrogated by TruSeq
EPIC alone, but also from sites interrogated by
both methods. When validated in larger and inde
pendent studies, the newly identified sites can
generate new knowledge and hypotheses that sti
mulate further research in understanding the role
of DNA methylation in disease development and
progression. Overall, our data suggest that TruSeq
EPIC may represent a powerful and improved
approach to interrogate the methylome and dis
cover novel disease-associated methylation in
human tissue in large cohorts.

Material and methods
Breast tissue samples and DNA extraction

This study included 11 breast tissue samples, including
3 normal (K), 4 tumour (T), and 4 matched adjacent
normal (AN) breast tissue samples. Normal breast
tissue samples were collected from healthy women
with no history of breast cancer by the Susan
G. Komen Tissue Bank, while breast tumour and
matched histologically normal, adjacent tissue sam
ples were collected from patients with primary
untreated breast cancer at the Indiana University
Simon Cancer Centre Tissue Bank. In general, adja
cent normal tissue was excised within the same body
site, but away from the cancer lesion macroscopically,
and was confirmed to be histologically normal. The
distance from the cancer margin to the area of the
breast from which the adjacent normal tissue was
taken varied case-by-case, but generally had
a minimal distance of 3 cm. Normal and tumour
samples were matched on race and age (within
a year). Basic characteristics of the cohort are provided
in Table 1. All breast tissue samples were snap-frozen
in liquid nitrogen within five minutes of removal and
determined to be of high quality through histological
and molecular quality control tests. Tumour samples
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were pathologically verified for high tumour content.
Genomic DNA was extracted from freshly frozen
normal, tumour and adjacent-normal breast tissue
samples using the Qiagen DNeasy Blood and Tissue
Kit (Qiagen Venlo, Netherlands). Extracted DNA was
first evaluated for its quantity and quality using
Agilent TapeStation 4200 (Agilent Technologies,
Santa Clara, CA, USA) electrophoresis and Thermo
Fisher Qubit 3.0 (Thermo Fisher Scientific, Waltham,
MA, USA) fluorometry technologies.
Genome-wide DNA methylation profiling
using TruSeq EPIC
Genome-wide DNA methylation profiling was
performed using the Illumina TruSeq Methyl
Capture EPIC library Prep Kit [15] and NGS tech
nology for genomic DNA sequencing. Five hun
dred nanograms of high-quality genomic DNA
were used for library preparation. Specifically,
DNA library preparation first included fragmenta
tion to an average size of 150–200bp using
a Covaris S2 ultrasonicator (Covaris Inc.,
Wobnurn, MA, USA), followed by end-repair, 3
A-tailing, and adaptor ligation. Libraries were then
pooled in groups of four in equal aliquot, on
which two rounds of hybridization and capture
using Illumina-optimized EPIC probe sets (cover
ing >3.3 million targeted CpG sites), bisulphite
conversion, and amplification were performed.
Five percent PhiX DNA (Illumina Inc.) was
added to each library pool during cluster amplifi
cation to boost diversity. Construction of DNA
libraries and subsequent processing and DNA
sequencing of paired-end reads (2 × 100nt reads)
were performed according to the standard
Illumina protocol using the HiSeq4000 sequencing
systems (Illumina Inc.).
TruSeq EPIC data processing

Raw sequencing reads were trimmed to remove
both poor quality calls and adapters using Trim
Galore! v0.4.4 [38]. Trimmed reads were then
aligned to the Genome Reference Consortium
human genome build 37 (hg19/GRCH37) [39]
using Bismark v0.19.0 [40]. Duplicated reads
were removed and cytosine methylation calls
were extracted from the deduplicated reads.
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Methylation calls that overlap with the Illumina
EPIC-seq targets were used in downstream ana
lyses. Deduplicated reads on each cytosine locus
were used to determine the DNAm levels (β
values); a β value is evaluated as the ratio of the
number of sequenced methylated cytosine reads to
the total number of reads for each locus. Thus, β
values range from 0 (completely un-methylated) to
1 (completely methylated). A CpG site was
included in downstream analysis if it had a β
value determined with ≥10X total reads and was
present in each of our tissue samples. After quality
control a total of approximately 2.74 million CpG
probes remained.

EPIC-array data processing

Signal intensities and raw methylation β values were
extracted from Illumina’s GenomeStudio software.
Probes with data from two beads or fewer or with
signal detection p-values above 0.01 were removed.
Signal intensities were normalized and background
subtracted using negative control probes to generate
methylation β values. Methylation β values were
derived as the ratio of methylation probe intensity to
overall intensity. An average of 752,483 CpGs
remained after comprehensive quality control [17].
A summary of the key features of TruSeq EPIC
and EPIC-array platforms is presented in Table 6.

Evaluation of technical performance of TruSeq
EPIC

Comparative analysis of TruSeq EPIC and
EPIC-array

We first assessed mapping efficiency, sequencing
duplication rates, and sequencing bait specificities
of the DNA methylome of 11 samples generated
using TruSeq EPIC. We further examined the
number of CpG sites detected at different sequen
cing depth by TruSeq EPIC in each sample.

To compare TruSeq EPIC and EPIC-array, we only
considered the common CpG sites across the two
platforms in targeted regions with at least x10 cover
age from TruSeq EPIC data and were measured in
every sample. We used three metrics: (i) genome
coverage; (ii) methylation β values; (iii) identification
of differential methylation sites across tissue types.
First, we compared the coverage of the human epi
genome by both methods in the context of CpG
islands, genomic functions, regulatory regions, and
chromosomal distributions. CpG island coordinates
were obtained from UCSC genome browser, CpG
shores were defined as up to 2kb from CpG islands,
and CpG shelves were defined as up to 2kb from CpG
shores. Genomic feature regions (promotor, 5 -UTR,
exon, intron, 3 -UTR, and TSS) for unique genes
were downloaded from UCSC genome browser to
determine gene-centric coverage. Regulatory regions
were defined using ENCODE DNAse hypersensitivity
sites and FANTOM5 enhancers. Secondly, we com
pared methylation β values from TruSeq EPIC and
EPIC-array at the same CpG sites using Pearson

Genome-wide DNA methylation profiling using
EPIC-array

Genome-wide DNA methylation profiling was also
performed using the Illumina Infinium Methylation
EPIC Beadchip array (Illumina, San Diego, CA, USA)
following the manufacturer’s instructions. Two hun
dred fifty nanograms of high-quality genomic DNA
was subsequently bisulphite converted using the EZ
DNA Methylation Kit (Zymo Research, Irine, CA,
USA). Bisulphite-treated samples were then ampli
fied, fragmented, purified and hybridized onto the
EPIC Beadchip according to the manufacturer’s stan
dard protocol. The arrays were washed and scanned
using the Illumina HiScan System.

Table 6. Summary of the key features of TruSeq EPIC and the EPIC-array platforms.
TruSeq EPIC
EPIC-array

Technology
NGS-based
Microarray-based

Method
Methylation Sequencing
Targeted DNA Sequencing
Methylation Array

Resolution
Single base

DNA Amount
500ng

#CpGs
3.3 M

Analytic Pipeline*
+++

Cost **
++

Single base

250ng

850 K

+

+

*, The TruSeq EPIC requires an analytic pipeline on sequencing data, including alignment, base call, and QC criteria on sequencing depth; the EPICarray requires QC criteria that removes CpGs that could be affected by poor hybridization, such as CpGs close to known SNPs.
**, the cost is changing over time and also depends on different service providers and the number of samples being processed. As of early 2020, the
cost for TruSeq EPIC for a depth of 50 M reads generally ranges between $550-$650/sample, and the cost for EPIC-array generally ranges between
$350-$450/sample.
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correlation, scatter plots, distribution plots, and con
cordance of methylation β values. Lastly, we per
formed differential methylation analysis to illustrate
the utility of both methods for identifying differen
tially methylated CpG sites across breast tissue types.
For EPIC-array data, we used the ChAMP R package
[41] and applied a generalized linear model to regress
the β values on tissue types while controlling for age.
For TruSeq EPIC data, we used the DSS R package
[42,43] and applied generalized linear regression
model using the read counts. A CpG site was consid
ered differentially methylated when false discovery
rate (FDR) was less than 0.05 and the absolute differ
ence in β values was greater than 0.1. We then crossreferenced the differential methylation detected by the
two methods.
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